JAZZJazz Pharmaceuticals plc
Pharmaceutical Preparations
- Revenue
- $4.3B
- 4.9% YoY
- Operating margin
- -10.1%
- 157% YoY
- EBITDA
- −$389M
- 152% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $2.7B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear7% of revenueOver 10% of revenue
- Payouts exceed cash flowClear9% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear16% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $3.1B | $3.7B | $3.8B | $4.1B | $4.3B | 4.9% |
| Operating income | $170M | −$66M | $579M | $717M | −$430M | 160% |
| Net income | −$330M | −$224M | $415M | $560M | −$356M | 164% |
| Operating cash flow | $779M | $1.3B | $1.1B | $1.4B | $1.4B | 2.9% |
| Capex | $28M | $29M | $24M | $38M | $59M | 54% |
| Stock-based comp | $189M | $222M | $227M | $248M | $291M | 17% |
| Buybacks | $0 | $54K | $270M | $311M | $125M | 60% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $23M · 11
- Net
- −$23M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 103 | 125 |
| FY2024 | $16M | $17M | 75 | 93 |
| FY2023 | $15M | −$3M | 75 | 94 |
| FY2022 | $17M | $26M | 97 | 90 |
| FY2021 | $16M | $5M | 77 | 100 |